Liver transplantation for hepatocellular carcinoma

Taketoshi Suehiro, Takahiro Terashi, Satoko Shiotani, Yuji Soejima, Keizo Sugimachi

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The surgical management for hepatocellular carcinoma (HCC) is multiplicity. In Japan, liver resection has generally been considered to be the only curative treatment for HCC. The resectability of a tumor in cirrhotic patients, however, is limited by the diminished functional reserve of the cirrhotic liver and the attendant risk for intraoperative bleeding and postoperative liver failure. In cirrhotic patients, liver transplantation has been considered as the indication for HCC in many countries except Japan. Although the survival rate of patients with HCC who received liver transplants was poor in the early period, it later moved to the same level as for patients with other liver diseases. In 1993, living donor adult liver transplatation was started in Japan and it became an additional option for the treatment of HCC. A shortage of liver donors means that new methods of liver procurement must be explored. Domino liver transplantation using the livers of patients with familial amyloid polyneuropathy was also another option for advanced HCC. For the prevention of a recurrence of HCC, pre-, intra-, and postoperative chemotherapy have been performed after both liver resection and liver transplantation. We should also try to minimize intraoperative dissemination by surgical manipulation. Recently, potential gene therapies for HCC have been studied. Electroporation-mediated IL-12 gene therapy for HCC was found to be effective for both mIL-12-transferred HCC and for distant HCC. For patients with HCC accompanied by liver cirrhosis, liver transplantation remains the ultimate curative therapy. Immunologic and oncologic approaches to HCC can help prevent tumor recurrence and also help us to obtain better results after liver transplantation.

Original languageEnglish
Pages (from-to)S190-S194
JournalSurgery
Volume131
Issue number1 SUPPL.
DOIs
Publication statusPublished - Jan 1 2002

Fingerprint

Liver Transplantation
Hepatocellular Carcinoma
Liver
Japan
Genetic Therapy
Familial Amyloid Neuropathies
Recurrence
Electroporation
Living Donors
Liver Failure
Interleukin-12
Liver Cirrhosis
Liver Diseases
Neoplasms
Therapeutics
Survival Rate
Tissue Donors
Hemorrhage
Transplants
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Suehiro, T., Terashi, T., Shiotani, S., Soejima, Y., & Sugimachi, K. (2002). Liver transplantation for hepatocellular carcinoma. Surgery, 131(1 SUPPL.), S190-S194. https://doi.org/10.1067/msy.2002.119575

Liver transplantation for hepatocellular carcinoma. / Suehiro, Taketoshi; Terashi, Takahiro; Shiotani, Satoko; Soejima, Yuji; Sugimachi, Keizo.

In: Surgery, Vol. 131, No. 1 SUPPL., 01.01.2002, p. S190-S194.

Research output: Contribution to journalArticle

Suehiro, T, Terashi, T, Shiotani, S, Soejima, Y & Sugimachi, K 2002, 'Liver transplantation for hepatocellular carcinoma', Surgery, vol. 131, no. 1 SUPPL., pp. S190-S194. https://doi.org/10.1067/msy.2002.119575
Suehiro T, Terashi T, Shiotani S, Soejima Y, Sugimachi K. Liver transplantation for hepatocellular carcinoma. Surgery. 2002 Jan 1;131(1 SUPPL.):S190-S194. https://doi.org/10.1067/msy.2002.119575
Suehiro, Taketoshi ; Terashi, Takahiro ; Shiotani, Satoko ; Soejima, Yuji ; Sugimachi, Keizo. / Liver transplantation for hepatocellular carcinoma. In: Surgery. 2002 ; Vol. 131, No. 1 SUPPL. pp. S190-S194.
@article{9ce00d2889524e0f9a69d9d550afbe8e,
title = "Liver transplantation for hepatocellular carcinoma",
abstract = "The surgical management for hepatocellular carcinoma (HCC) is multiplicity. In Japan, liver resection has generally been considered to be the only curative treatment for HCC. The resectability of a tumor in cirrhotic patients, however, is limited by the diminished functional reserve of the cirrhotic liver and the attendant risk for intraoperative bleeding and postoperative liver failure. In cirrhotic patients, liver transplantation has been considered as the indication for HCC in many countries except Japan. Although the survival rate of patients with HCC who received liver transplants was poor in the early period, it later moved to the same level as for patients with other liver diseases. In 1993, living donor adult liver transplatation was started in Japan and it became an additional option for the treatment of HCC. A shortage of liver donors means that new methods of liver procurement must be explored. Domino liver transplantation using the livers of patients with familial amyloid polyneuropathy was also another option for advanced HCC. For the prevention of a recurrence of HCC, pre-, intra-, and postoperative chemotherapy have been performed after both liver resection and liver transplantation. We should also try to minimize intraoperative dissemination by surgical manipulation. Recently, potential gene therapies for HCC have been studied. Electroporation-mediated IL-12 gene therapy for HCC was found to be effective for both mIL-12-transferred HCC and for distant HCC. For patients with HCC accompanied by liver cirrhosis, liver transplantation remains the ultimate curative therapy. Immunologic and oncologic approaches to HCC can help prevent tumor recurrence and also help us to obtain better results after liver transplantation.",
author = "Taketoshi Suehiro and Takahiro Terashi and Satoko Shiotani and Yuji Soejima and Keizo Sugimachi",
year = "2002",
month = "1",
day = "1",
doi = "10.1067/msy.2002.119575",
language = "English",
volume = "131",
pages = "S190--S194",
journal = "Surgery",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "1 SUPPL.",

}

TY - JOUR

T1 - Liver transplantation for hepatocellular carcinoma

AU - Suehiro, Taketoshi

AU - Terashi, Takahiro

AU - Shiotani, Satoko

AU - Soejima, Yuji

AU - Sugimachi, Keizo

PY - 2002/1/1

Y1 - 2002/1/1

N2 - The surgical management for hepatocellular carcinoma (HCC) is multiplicity. In Japan, liver resection has generally been considered to be the only curative treatment for HCC. The resectability of a tumor in cirrhotic patients, however, is limited by the diminished functional reserve of the cirrhotic liver and the attendant risk for intraoperative bleeding and postoperative liver failure. In cirrhotic patients, liver transplantation has been considered as the indication for HCC in many countries except Japan. Although the survival rate of patients with HCC who received liver transplants was poor in the early period, it later moved to the same level as for patients with other liver diseases. In 1993, living donor adult liver transplatation was started in Japan and it became an additional option for the treatment of HCC. A shortage of liver donors means that new methods of liver procurement must be explored. Domino liver transplantation using the livers of patients with familial amyloid polyneuropathy was also another option for advanced HCC. For the prevention of a recurrence of HCC, pre-, intra-, and postoperative chemotherapy have been performed after both liver resection and liver transplantation. We should also try to minimize intraoperative dissemination by surgical manipulation. Recently, potential gene therapies for HCC have been studied. Electroporation-mediated IL-12 gene therapy for HCC was found to be effective for both mIL-12-transferred HCC and for distant HCC. For patients with HCC accompanied by liver cirrhosis, liver transplantation remains the ultimate curative therapy. Immunologic and oncologic approaches to HCC can help prevent tumor recurrence and also help us to obtain better results after liver transplantation.

AB - The surgical management for hepatocellular carcinoma (HCC) is multiplicity. In Japan, liver resection has generally been considered to be the only curative treatment for HCC. The resectability of a tumor in cirrhotic patients, however, is limited by the diminished functional reserve of the cirrhotic liver and the attendant risk for intraoperative bleeding and postoperative liver failure. In cirrhotic patients, liver transplantation has been considered as the indication for HCC in many countries except Japan. Although the survival rate of patients with HCC who received liver transplants was poor in the early period, it later moved to the same level as for patients with other liver diseases. In 1993, living donor adult liver transplatation was started in Japan and it became an additional option for the treatment of HCC. A shortage of liver donors means that new methods of liver procurement must be explored. Domino liver transplantation using the livers of patients with familial amyloid polyneuropathy was also another option for advanced HCC. For the prevention of a recurrence of HCC, pre-, intra-, and postoperative chemotherapy have been performed after both liver resection and liver transplantation. We should also try to minimize intraoperative dissemination by surgical manipulation. Recently, potential gene therapies for HCC have been studied. Electroporation-mediated IL-12 gene therapy for HCC was found to be effective for both mIL-12-transferred HCC and for distant HCC. For patients with HCC accompanied by liver cirrhosis, liver transplantation remains the ultimate curative therapy. Immunologic and oncologic approaches to HCC can help prevent tumor recurrence and also help us to obtain better results after liver transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0036165012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036165012&partnerID=8YFLogxK

U2 - 10.1067/msy.2002.119575

DO - 10.1067/msy.2002.119575

M3 - Article

C2 - 11821809

AN - SCOPUS:0036165012

VL - 131

SP - S190-S194

JO - Surgery

JF - Surgery

SN - 0039-6060

IS - 1 SUPPL.

ER -